Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 3, 2024
Daily News
September 3, 2024
- Aculys Pharma Files Diazepam Nasal Spray in Japan
September 3, 2024
- Japan Study Finds No Evidence of Increased Cancer Risk for Sitagliptin
September 3, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- PET Agent Vizamyl Approved for Use in Patients on Anti-Aβ Therapy
September 3, 2024
- Nichi-Iko to Finally Roll Out Halaven AG Nearly 4 Years after Approval
September 3, 2024
- Ex-Sanofi Exec John Pulvar Tapped as New CEO of Ferring Japan
September 3, 2024
- BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- Janssen Offloads Nizoral Cream to Teikoku Seiyaku
September 3, 2024
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Mounjaro Wins Podium in July GP Rep Promotion Rankings: Intage
September 3, 2024
- Takeda to Discontinue Kenketu Albuminate amid Falling Demand
September 3, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…